Synchronous bilateral breast carcinoma

Summary

Synchronous bilateral breast carcinoma (MONDO:0003983) is a cancer and 2 clinical trials. Top therapeutic interventions include anastrozole, exemestane, and letrozole. A subtype of bilateral breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	synchronous bilateral breast carcinoma
Mondo ID	MONDO:0003983
DOID	DOID:6742
NCIT	C40370
UMLS	C1515107
MedGen	271163
Is cancer (heuristic)	yes

Disease family

This is a subtype of bilateral breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › bilateral breast carcinoma › synchronous bilateral breast carcinoma

Related subtypes (1): lipid-rich breast carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01272037	PHASE3	ACTIVE_NOT_RECRUITING	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT04457596	PHASE3	ACTIVE_NOT_RECRUITING	T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ANASTROZOLE	4	1
EXEMESTANE	4	1
LETROZOLE	4	1
TRASTUZUMAB EMTANSINE	4	1
TUCATINIB	4	1